Visual snow syndrome: a comparison between an Italian and British population

M. Viana, F. Puledda and P. J. Goadsby

Headache Group, Department of Basic and Clinical Neurosciences, King’s College London, London, UK; Headache Centre, Neurocentre of Southern Switzerland (NSI), Regional Hospital Lugano, Switzerland; and NIHR-Wellcome Trust King’s Clinical Research Facility, SLaM Biomedical Research Centre, King’s College Hospital, London, UK

Keywords: geographical, palinopsia, photophobia, visual snow, visual snow syndrome

Background and purpose: Visual snow manifests as a pan-field, dynamic visual disturbance described as continuous television static-like tiny flickering dots. Current diagnostic criteria further require at least two additional symptoms for visual snow syndrome (VSS) from: palinopsia (afterimages and trailing); entoptic phenomena (floaters, blue field entoptic phenomenon, photopsia, self-light of the eye); photophobia and nyctalopia. Our objective was to compare the phenotype of VSS in an Italian and British population.

Methods: Patients with VSS were characterized clinically using the current criteria. An online survey was prepared in collaboration with the patient group Eye-on-Vision. Patients were directed to the site if they contacted us by email asking to be involved in research. After data collection, we compared the phenotypic characteristics of a subgroup of British versus Italian patients taking part in the survey. As we expected more responses from the UK, we matched 100 UK patients for gender and age with our Italian cohort.

Results: Patients were enrolled from the UK (n = 100) and Italy (n = 100). The populations had similar demography. After multiple correction testing there were no differences in VSS features between the two groups. The same was true for the prevalence of migraine and previous use of recreational drugs.

Conclusion: This is the first study comparing the phenotype of VSS between two distinct populations. Our findings suggest that the visual snow phenotype, as well as migraine comorbidity, is similar across the two groups.

Introduction

Visual snow manifests as a pan-field, dynamic visual disturbance described as continuous television static-like tiny flickering dots, termed ‘static’ or snow [1]. Current diagnostic criteria for the complete visual snow syndrome (VSS) require at least two additional visual symptoms from: palinopsia (afterimages and trailing); entoptic phenomena (floaters, blue field entoptic phenomenon, photopsia, self-light of the eye); photophobia and nyctalopia [1]. Migraine and tinnitus are common comorbidities of visual snow, reported in up to three-quarters of patients [2,3].

So far, systematic collections of the VSS phenotype on wide populations from a specific geographical area have been performed in only two countries: in 78 subjects in the USA [1] and 58 in the Netherlands [4]. A formal comparison of two groups affected by visual snow and belonging to different geographical and cultural backgrounds has not been conducted.

Our objective was to compare the phenotype of VSS, including its common clinical characteristics, in an Italian and UK population of affected subjects. The results were presented in preliminary form at the 4th Congress of the European Academy of Neurology (Lisbon, Portugal, 16–19 June 2018) [5].
Methods

This study was part of a web-based survey conducted in a larger population with VSS [6].

In the present study, we conducted a cross-sectional analysis on two different subpopulations of subjects taking part in the online survey: one from Italy and the other from the UK. All of the analysed subjects fulfilled the complete diagnosis of VSS, according to the current criteria [1]. Data for the study were collected between April 2016 and May 2018. The study was approved by the KCL Research Ethics Panel. The online survey we used was prepared in English in collaboration with the patient group Eye-on-Vision [6]. For patients who required a translation, authors M.V. and F.P. translated the questionnaire into Italian following the appropriate guidelines [7].

After data collection, we compared the phenotypic characteristics of UK patients versus Italian patients. As we expected more responses from the UK, we matched 100 UK patients for gender and age with our Italian subpopulation. Comparisons between the two groups of patients were performed with the Mann–Whitney U-test or chi-squared test for continuous or categorical variables, respectively. Due to multiple testing, adjusted \( P \) values based on the Bonferroni correction are presented with a significance level set at \( P < 0.0026 \).

Results

Patients were enrolled from the UK \((n = 100)\) and Italy \((n = 100)\). Table 1 shows demographic and clinical data from the two groups. After correction for multiple testing, we found that all the VSS features, in particular the history of the disease, the types of static reported and the frequency of additional visual symptoms, were no different between the two groups. The same was true for the prevalence of comorbidities (migraine and tinnitus) and previous use of recreational drugs.

Discussion

Visual snow syndrome is a poorly recognized neurological condition, characterized by persistent and disabling visual disturbances that are not matched by any underlying structural, drug-related, psychiatric or epileptic cause. The diagnosis can be formulated based on the fulfilment of specific clinical criteria that have been validated in a large population [6].

This is the first study comparing the clinical phenotype of two populations of patients experiencing VSS, who spoke different languages and had different geographical and cultural backgrounds. Our findings show that the clinical criteria available for VSS are generalizable to different populations and that when these criteria are carefully followed and translated they can be used in different languages.

It is important to demonstrate that a syndrome characterized by subjective symptoms and without objective measures to aid the diagnosis presents with similar clinical features in populations with different languages and genetic backgrounds. Whether clinical

| Table 1 Demographic and clinical data of the two populations of patients with visual snow syndrome |
|-----------------------------------------------|------------------|------------------|------------------|---------------|
|                                              | UK \((n = 100)\) | Italy \((n = 100)\) |     \( U\)-test     | Chi-squared test |
| Female, \(n\)                                | 53               | 53               | 0.88             |               |
| Age, years                                   | 30 ± 10          | 32 ± 10          | 0.1              |               |
| History of disease                           |                  |                  |                  |               |
| Sudden onset, \(n\)                          | 32               | 51               | 0.009            |               |
| VSS age of onset, years                      | 24 ± 10          | 22 ± 10          | 0.44             |               |
| Disease years                                | 19 ± 14          | 15 ± 14          | 0.09             |               |
| VSS: static type, \(n\)                      |                  |                  |                  |               |
| Black and white                              | 65               | 58               | 0.30             |               |
| Coloured                                     | 40               | 23               | 0.01             |               |
| Flashing                                     | 50               | 44               | 0.39             |               |
| Transparent                                  | 41               | 54               | 0.06             |               |
| Number of static types                       |                  |                  |                  |               |
| Mean ± SD                                    | 1.96 ± 1.1       | 1.79 ± 1.1       | 0.28             |               |
| Median; IQR                                  | 2; 2–3           | 1; 1–2           |                  |               |
| VSS: additional symptoms, \(n\)              |                  |                  |                  |               |
| Afterimages                                  | 83               | 70               | 0.03             |               |
| Trailing                                     | 66               | 53               | 0.06             |               |
| Blue field entoptic phenomenon               | 78               | 76               | 0.73             |               |
| Floaters                                     | 83               | 93               | 0.03             |               |
| Self-light of the eye                        | 70               | 65               | 0.45             |               |
| Flashes                                      | 70               | 52               | 0.009            |               |
| Nystagmus                                    | 79               | 76               | 0.61             |               |
| Photophobia                                  | 74               | 87               | 0.02             |               |
| Number of VSS symptoms                       |                  |                  |                  |               |
| Median; IQR                                  | 6; 5–7           | 6; 5–7           | 0.63             |               |
| Medical history and comorbidities, \(n\)     |                  |                  |                  |               |
| Migraine                                     | 69               | 70               | 0.96             |               |
| Tinnitus                                     | 79               | 63               | 0.01             |               |
| Previous use of recreational drugs           | 26               | 21               | 0.40             |               |

IQR, interquartile range; VSS, visual snow syndrome. Data are mean ± SD, unless otherwise stated. UK patients were matched for gender and age with our Italian subpopulation. Due to multiple testing across 19 variables, adjusted \( P \) values based on the Bonferroni correction were considered. The significance level was therefore lowered to \( P < 0.0026 \). \( P \) values for Mann–Whitney \( U\)-test or chi-squared test are shown.
similarities also correspond to a similar prevalence of VSS in these different populations remains to be determined.

A methodological limitation of the study could arise from the process of translation of the questionnaire from the English version to the Italian one. In this respect, it should be noted that the authors who performed the translations are of Italian origin and have long experience in working in the English language. Furthermore, ad hoc guidelines were followed in order to ensure a high-quality translation (7). It is possible that strict multiple comparison correction could have masked some relevant differences between the two populations. Without correction, the Italian population had a higher prevalence of certain visual symptoms, particularly of photophobia. Given the geographical and environmental differences between the two countries, it is indeed possible that different exposure to sunlight could have affected the Italian subjects with VSS.

In conclusion, this is the first study comparing the phenotype of VSS between two geographically distinct and culturally different populations. Our findings suggest that the VSS phenotype, as well as the comorbidities of migraine and tinnitus, are similar across different populations.

Acknowledgements

The authors thank all the patients who took part in the survey and who volunteered to share their symptoms and experience with us, allowing this research to take place. This study represents independent research part funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre (BRC-1215-20018). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The study was in part supported by the Visual Snow Initiative and by crowdfunding from the self-help group for VSS, the Eye-on-Vision Foundation.

Disclosure of conflicts of interest

M.V. and F.P. declare no financial or other conflicts of interest. P.J.G. reports grants and personal fees from Amgen and Eli-Lilly and Company, a grant from Celgene, and personal fees from Alder Biopharmaceuticals, Aeon Biopharma, Allergan, Biohaven Pharmaceuticals Inc., Clexio, Electrocore LLC, eNeura, Epalex, Impel Neuropharma, Mundipharma, Novartis, Pfizer, Santara Therapeutics, Teva Pharmaceuticals, Trigemina Inc. and WL Gore, and personal fees from MedicoLegal work, the Massachusetts Medical Society, Up-to-Date, Oxford University Press, and Wolters Kluwer; and a patent magnetic stimulation for headache assigned to eNeura without fee.

Data availability statement

Data are available from the corresponding author upon reasonable request.

References

1. Schankin CJ, Maniyar FH, Digre KB, Goadsby PJ. ‘Visual snow’ - a disorder distinct from persistent migraine aura. Brain 2014; 137: 1419–1428.
2. Puledda F, Schankin C, Digre K, Goadsby PJ. Visual snow syndrome: what we know so far. Curr Opin Neurol 2018; 31: 52–58.
3. Metzler AI, Robertson CE. Visual snow syndrome: proposed criteria, clinical implications, and pathophysiology. Curr Neurol Neurosci Rep 2018; 18: 52.
4. van Dongen RM, Waaijer LC, Onderwater GLJ, Ferrari MD, Terwindt GM. Treatment effects and comorbid diseases in 58 patients with visual snow. Neurology 2019; 93: e398–e403.
5. Viana M, Puledda F, Goadsby PJ. Visual snow syndrome: comparison between an Italian and English population. Eur J Neurol 2018; 25: 589.
6. Puledda F, Schankin C, Goadsby PJ. Visual snow syndrome. A clinical and phenotypical description of 1100 cases. Neurology 2020; 94(6): e564–e574.
7. Steiner TJ, Jensen R, Katsarava Z, et al. Translation, and the preservation of original meaning, of materials developed to improve headache management: translation protocol for hybrid documents. J Headache Pain 2019; 20: 57.